Annual Operating Profit
$10.46 M
+$23.47 M+180.37%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual operating income is $10.46 million, with the most recent change of +$23.47 million (+180.37%) on December 31, 2023.
- During the last 3 years, PLX annual operating profit has risen by +$7.75 million (+285.98%).
- PLX annual operating profit is now at all-time high.
Performance
PLX Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Profit
$3.99 M
+$6.42 M+264.44%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly operating income is $3.99 million, with the most recent change of +$6.42 million (+264.44%) on September 30, 2024.
- Over the past year, PLX quarterly operating profit has increased by +$5.88 million (+311.50%).
- PLX quarterly operating profit is now -80.46% below its all-time high of $20.42 million, reached on June 30, 2023.
Performance
PLX Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Operating Profit
-$8.91 M
+$5.88 M+39.76%
September 30, 2024
Summary
- As of February 8, 2025, PLX TTM operating income is -$8.91 million, with the most recent change of +$5.88 million (+39.76%) on September 30, 2024.
- Over the past year, PLX TTM operating profit has dropped by -$22.49 million (-165.59%).
- PLX TTM operating profit is now -165.59% below its all-time high of $13.58 million, reached on September 30, 2023.
Performance
PLX TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Profit Formula
Operating Profit = Gross Profit − Operating Expenses
PLX Operating Profit Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +180.4% | +311.5% | -165.6% |
3 y3 years | +286.0% | +311.5% | -165.6% |
5 y5 years | +154.2% | +311.5% | -165.6% |
PLX Operating Profit Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +151.1% | -80.5% | +169.9% | -165.6% | +56.5% |
5 y | 5-year | at high | +151.1% | -80.5% | +143.5% | -165.6% | +56.5% |
alltime | all time | at high | +128.6% | -80.5% | +123.3% | -165.6% | +77.0% |
Protalix BioTherapeutics Operating Profit History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $3.99 M(-264.4%) | -$8.91 M(-39.8%) |
Jun 2024 | - | -$2.43 M(-50.0%) | -$14.79 M(-283.4%) |
Mar 2024 | - | -$4.86 M(-13.5%) | $8.06 M(-22.9%) |
Dec 2023 | $10.46 M(-180.4%) | -$5.62 M(+197.6%) | $10.46 M(-23.0%) |
Sep 2023 | - | -$1.89 M(-109.2%) | $13.58 M(+10.0%) |
Jun 2023 | - | $20.42 M(-930.5%) | $12.34 M(-190.7%) |
Mar 2023 | - | -$2.46 M(-1.4%) | -$13.60 M(+4.5%) |
Dec 2022 | -$13.01 M(-36.4%) | -$2.50 M(-20.2%) | -$13.01 M(-19.8%) |
Sep 2022 | - | -$3.13 M(-43.4%) | -$16.23 M(+8.3%) |
Jun 2022 | - | -$5.52 M(+195.4%) | -$14.98 M(-19.6%) |
Mar 2022 | - | -$1.87 M(-67.2%) | -$18.63 M(-9.0%) |
Dec 2021 | -$20.46 M(-855.1%) | -$5.71 M(+202.7%) | -$20.46 M(+71.7%) |
Sep 2021 | - | -$1.89 M(-79.4%) | -$11.92 M(-5.5%) |
Jun 2021 | - | -$9.17 M(+147.4%) | -$12.61 M(+121.8%) |
Mar 2021 | - | -$3.71 M(-230.5%) | -$5.69 M(-309.9%) |
Dec 2020 | $2.71 M(-125.3%) | $2.84 M(-210.0%) | $2.71 M(+30.9%) |
Sep 2020 | - | -$2.58 M(+15.3%) | $2.07 M(-33.4%) |
Jun 2020 | - | -$2.24 M(-147.7%) | $3.11 M(-734.5%) |
Mar 2020 | - | $4.69 M(+113.3%) | -$490.00 K(-95.4%) |
Dec 2019 | -$10.72 M(-44.5%) | $2.20 M(-242.5%) | -$10.72 M(-35.4%) |
Sep 2019 | - | -$1.54 M(-73.6%) | -$16.59 M(-11.7%) |
Jun 2019 | - | -$5.84 M(+5.5%) | -$18.79 M(-4.6%) |
Mar 2019 | - | -$5.53 M(+50.7%) | -$19.69 M(+2.0%) |
Dec 2018 | -$19.31 M(-44.1%) | -$3.67 M(-1.8%) | -$19.31 M(-23.4%) |
Sep 2018 | - | -$3.74 M(-44.5%) | -$25.22 M(-13.8%) |
Jun 2018 | - | -$6.74 M(+30.9%) | -$29.24 M(-12.2%) |
Mar 2018 | - | -$5.15 M(-46.2%) | -$33.30 M(-3.5%) |
Dec 2017 | -$34.52 M(+4.1%) | -$9.58 M(+23.4%) | -$34.52 M(+2.6%) |
Sep 2017 | - | -$7.76 M(-28.1%) | -$33.66 M(+3.4%) |
Jun 2017 | - | -$10.80 M(+69.8%) | -$32.54 M(+2.8%) |
Mar 2017 | - | -$6.37 M(-27.0%) | -$31.66 M(-4.5%) |
Dec 2016 | -$33.16 M(+40.1%) | -$8.72 M(+31.2%) | -$33.16 M(+3.2%) |
Sep 2016 | - | -$6.65 M(-33.1%) | -$32.14 M(+5.4%) |
Jun 2016 | - | -$9.93 M(+26.3%) | -$30.50 M(+16.6%) |
Mar 2016 | - | -$7.86 M(+2.1%) | -$26.15 M(+10.5%) |
Dec 2015 | -$23.67 M(-17.1%) | -$7.70 M(+53.9%) | -$23.67 M(-10.4%) |
Sep 2015 | - | -$5.00 M(-10.4%) | -$26.41 M(-4.4%) |
Jun 2015 | - | -$5.58 M(+3.7%) | -$27.61 M(+0.5%) |
Mar 2015 | - | -$5.38 M(-48.4%) | -$27.48 M(-3.8%) |
Dec 2014 | -$28.56 M(-16.2%) | -$10.44 M(+68.1%) | -$28.56 M(-18.9%) |
Sep 2014 | - | -$6.21 M(+14.0%) | -$35.22 M(+1.6%) |
Jun 2014 | - | -$5.45 M(-15.8%) | -$34.66 M(-4.0%) |
Mar 2014 | - | -$6.47 M(-62.2%) | -$36.10 M(+6.0%) |
Dec 2013 | -$34.06 M(+179.8%) | -$17.09 M(+202.8%) | -$34.06 M(+25.5%) |
Sep 2013 | - | -$5.64 M(-18.1%) | -$27.14 M(+0.3%) |
Jun 2013 | - | -$6.89 M(+55.7%) | -$27.05 M(+156.7%) |
Mar 2013 | - | -$4.43 M(-56.4%) | -$10.54 M(-13.4%) |
Dec 2012 | -$12.17 M(-66.7%) | -$10.17 M(+82.9%) | -$12.17 M(+12.1%) |
Sep 2012 | - | -$5.56 M(-157.8%) | -$10.86 M(-22.8%) |
Jun 2012 | - | $9.62 M(-258.6%) | -$14.07 M(-56.3%) |
Mar 2012 | - | -$6.07 M(-31.5%) | -$32.18 M(+3.3%) |
Dec 2011 | -$36.53 M | -$8.86 M(+1.0%) | -$31.15 M(+0.0%) |
Sep 2011 | - | -$8.77 M(+3.3%) | -$31.14 M(+23.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2011 | - | -$8.49 M(+68.4%) | -$25.22 M(-4.3%) |
Mar 2011 | - | -$5.04 M(-43.1%) | -$26.36 M(-10.5%) |
Dec 2010 | -$29.97 M(-6.3%) | -$8.85 M(+210.7%) | -$29.44 M(-17.3%) |
Sep 2010 | - | -$2.85 M(-70.4%) | -$35.60 M(-8.2%) |
Jun 2010 | - | -$9.62 M(+18.5%) | -$38.80 M(+10.7%) |
Mar 2010 | - | -$8.12 M(-45.9%) | -$35.05 M(+9.6%) |
Dec 2009 | -$31.97 M(+32.3%) | -$15.02 M(+148.3%) | -$31.97 M(+37.5%) |
Sep 2009 | - | -$6.05 M(+2.9%) | -$23.25 M(-2.8%) |
Jun 2009 | - | -$5.87 M(+16.6%) | -$23.92 M(+4.2%) |
Mar 2009 | - | -$5.04 M(-20.0%) | -$22.94 M(-5.1%) |
Dec 2008 | -$24.17 M(-29.3%) | -$6.29 M(-6.3%) | -$24.17 M(-27.8%) |
Sep 2008 | - | -$6.72 M(+37.2%) | -$33.50 M(+0.9%) |
Jun 2008 | - | -$4.90 M(-21.8%) | -$33.21 M(-11.8%) |
Mar 2008 | - | -$6.26 M(-59.9%) | -$37.65 M(+7.1%) |
Dec 2007 | -$34.16 M(+249.6%) | -$15.62 M(+142.8%) | -$35.16 M(+51.0%) |
Sep 2007 | - | -$6.43 M(-31.1%) | -$23.28 M(+20.1%) |
Jun 2007 | - | -$9.34 M(+146.9%) | -$19.39 M(+43.1%) |
Mar 2007 | - | -$3.78 M(+1.2%) | -$13.55 M(+18.8%) |
Dec 2006 | -$9.77 M(+68.8%) | -$3.73 M(+47.2%) | -$11.41 M(-14.8%) |
Sep 2006 | - | -$2.54 M(-27.5%) | -$13.39 M(+23.0%) |
Jun 2006 | - | -$3.50 M(+113.7%) | -$10.89 M(+46.9%) |
Mar 2006 | - | -$1.64 M(-71.4%) | -$7.42 M(+28.1%) |
Dec 2005 | -$5.79 M(+139.5%) | -$5.72 M(>+9900.0%) | -$5.79 M(+146.3%) |
Sep 2005 | - | -$35.90 K(+76.0%) | -$2.35 M(-0.3%) |
Jun 2005 | - | -$20.40 K(+87.2%) | -$2.36 M(-1.6%) |
Mar 2005 | - | -$10.90 K(-99.5%) | -$2.40 M(-0.8%) |
Dec 2004 | -$2.42 M(+1539.8%) | -$2.28 M(+5101.6%) | -$2.42 M(+1225.1%) |
Sep 2004 | - | -$43.90 K(-26.7%) | -$182.40 K(+6.4%) |
Jun 2004 | - | -$59.90 K(+101.7%) | -$171.50 K(+20.3%) |
Mar 2004 | - | -$29.70 K(-39.3%) | -$142.60 K(-3.3%) |
Dec 2003 | -$147.40 K(-11.1%) | -$48.90 K(+48.2%) | -$147.50 K(-2.4%) |
Sep 2003 | - | -$33.00 K(+6.5%) | -$151.10 K(-1.8%) |
Jun 2003 | - | -$31.00 K(-10.4%) | -$153.90 K(-3.7%) |
Mar 2003 | - | -$34.60 K(-34.1%) | -$159.80 K(-3.6%) |
Dec 2002 | -$165.80 K(-57.0%) | -$52.50 K(+46.6%) | -$165.80 K(-38.5%) |
Sep 2002 | - | -$35.80 K(-3.0%) | -$269.50 K(-7.8%) |
Jun 2002 | - | -$36.90 K(-9.1%) | -$292.40 K(-8.8%) |
Mar 2002 | - | -$40.60 K(-74.0%) | -$320.50 K(-16.9%) |
Dec 2001 | -$385.80 K(+1.0%) | -$156.20 K(+166.1%) | -$385.70 K(-14.3%) |
Sep 2001 | - | -$58.70 K(-9.7%) | -$449.80 K(+10.6%) |
Jun 2001 | - | -$65.00 K(-38.6%) | -$406.70 K(-3.1%) |
Mar 2001 | - | -$105.80 K(-52.0%) | -$419.50 K(+9.8%) |
Dec 2000 | -$381.90 K(-53.2%) | -$220.30 K(+1312.2%) | -$381.90 K(+26.2%) |
Sep 2000 | - | -$15.60 K(-79.9%) | -$302.70 K(-57.4%) |
Jun 2000 | - | -$77.80 K(+14.1%) | -$710.90 K(-12.5%) |
Mar 2000 | - | -$68.20 K(-51.7%) | -$812.00 K(-0.5%) |
Dec 1999 | -$816.20 K(-30.5%) | -$141.10 K(-66.7%) | -$816.20 K(+20.9%) |
Sep 1999 | - | -$423.80 K(+136.9%) | -$675.10 K(+168.6%) |
Jun 1999 | - | -$178.90 K(+147.1%) | -$251.30 K(+247.1%) |
Mar 1999 | - | -$72.40 K | -$72.40 K |
Dec 1998 | -$1.17 M(+614.2%) | - | - |
Dec 1997 | -$164.40 K(+272.8%) | - | - |
Dec 1996 | -$44.10 K | - | - |
FAQ
- What is Protalix BioTherapeutics annual operating income?
- What is the all time high annual operating profit for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual operating profit year-on-year change?
- What is Protalix BioTherapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly operating profit year-on-year change?
- What is Protalix BioTherapeutics TTM operating income?
- What is the all time high TTM operating profit for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics TTM operating profit year-on-year change?
What is Protalix BioTherapeutics annual operating income?
The current annual operating profit of PLX is $10.46 M
What is the all time high annual operating profit for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual operating income is $10.46 M
What is Protalix BioTherapeutics annual operating profit year-on-year change?
Over the past year, PLX annual operating income has changed by +$23.47 M (+180.37%)
What is Protalix BioTherapeutics quarterly operating income?
The current quarterly operating profit of PLX is $3.99 M
What is the all time high quarterly operating profit for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly operating income is $20.42 M
What is Protalix BioTherapeutics quarterly operating profit year-on-year change?
Over the past year, PLX quarterly operating income has changed by +$5.88 M (+311.50%)
What is Protalix BioTherapeutics TTM operating income?
The current TTM operating profit of PLX is -$8.91 M
What is the all time high TTM operating profit for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high TTM operating income is $13.58 M
What is Protalix BioTherapeutics TTM operating profit year-on-year change?
Over the past year, PLX TTM operating income has changed by -$22.49 M (-165.59%)